Mobile

A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROUSAL...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005381-39

A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROUSAL DISORDER (FSAD)

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Assess the effect of 3 doses (1, 3 and 10 mg) of CP-866,087 vs. placebo on female arousal, desire, orgasm and distress in pre-menopausal women on oral contraceptives suffering primarily from Female Sexual Arousal Disorder (FSAD).

Critère d'inclusion

  • Female Sexual Dysfunction (FSD)

Liens